PRostate Cancer Plasma Integrative Multi-modal Evaluation
Recruiting now
Conditions studied: Metastatic Prostate Cancer
In brief
The study aims to develop PRIME (PRostate cancer plasma Integrative Multi-modal Evaluation) liquid biopsy test and to implement its use to query prospectively collected samples in advanced prostate cancer (PCa) clinical trials and/or clinical settings. In order to maximise the utility of liquid biopsies for advanced PCa, PRIME is focused on the development of novel computational and sequencing approaches that integrate multiple information from plasma circulating elements: i) cell free DNA (cfDNA) gene mutation data with accurate quantitation of cfDNA structural genomic changes, ii) cfDNA genomic profiling with cfDNA methylation status, and iii) the information provided by extracellular vesicles (EVs) and EV-associated cargo (including DNA, RNA and proteins).
Key facts
- Study ID
- NCT06981377
- Run by
- Santa Chiara Hospital
- People needed
- 800
- Starts
- 2019-05-07
- Expected to finish
- 2027-01-31
- Last updated by the study team
- 2025-05-20
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of prostate cancer
- Eligible for prostate cancer pharmacological treatment
- Given consent to study participation
You may not qualify if…
- Histological diagnosis other than prostate cancer
Where it is running
- Istituto Romagnolo per lo Studio dei Tumori — Meldola, Forlì-Cesena, Italy (enrolling)
- Azienda Ospedaliera San Luigi — Orbassano, Torino, Italy (enrolling)
- Istituto Oncologico Veneto — Padova, Italy (enrolling)
- Santa Chiara Hospital — Trento, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.